CTLA4 and neoplasm: Currently, there is no reliable biomarker predicting or correlating with irAEs, but several ones are under investigation including serum IL-6, IL-17, soluble CTLA-4 (sCTLA-4), absolute lymphocyte count, and tumor mutation burden (52–55).